![Marc D. Doubleday](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Marc D. Doubleday
No más puestos en curso
Historial de carrera de Marc D. Doubleday
Antiguos cargos conocidos de Marc D. Doubleday.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | Director Técnico/Científico/I+D | 01/01/1988 | 10/11/2009 |
Formación de Marc D. Doubleday.
Northwestern University | Graduate Degree |
Estadísticas
Internacional
Estados Unidos | 3 |
Operativa
Chief Tech/Sci/R&D Officer | 1 |
Graduate Degree | 1 |
Sectorial
Health Technology | 2 |
Consumer Services | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 1 |
---|---|
Northfield Laboratories, Inc.
![]() Northfield Laboratories, Inc. BiotechnologyHealth Technology The Company's principal activity is to develop, manufacture, market and distribute a hemoglobin-based blood substitute product. The Company's product, PolyHeme(R) blood substitute, provides an alternative to transfused blood for use in the treatment of acute blood loss. The company uses a proprietary process of separation, filtration, chemical modification purification and formulation to produce PolyHeme. PolyHeme is designed to avoid potential undesirable effects such as vasoconstriction, kidney dysfunction, liver dysfunction and gastrointestinal distress. Clinical trials of PolyHeme have been conducted at multiple locations in the United States. The company has entered into license agreements with Pfizer Inc and Hemocare Ltd an Israeli corporation to develop manufacture and distribute PolyHeme in certain European, Middle Eastern and African countries. The Company is in development stage. | Health Technology |
- Bolsa de valores
- Insiders
- Marc D. Doubleday
- Experiencia